APO Research
Talk to an analyst

APO RESEARCH · REPORT

Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)

Compare research editions
View pricing & licenses

Selected research

Industry Research

Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Research Report 2026

27 December 2025125 pages

Choose your research edition.

Industry ResearchTreatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) include Tonghua Zhongsheng Pharmaceutical, Zhengzhou Taifeng Pharmaceutical, Shapuaisi Pharma, Luoxin Pharmaceutical, Zydus Pharms, Teva, Pfizer, Avet Pharmaceuticals and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market by Company

Tonghua Zhongsheng Pharmaceutical

Zhengzhou Taifeng Pharmaceutical

Shapuaisi Pharma

Luoxin Pharmaceutical

Zydus Pharms

Teva

Pfizer

Avet Pharmaceuticals

AstraZeneca

Alnylam Pharmaceuticals

Akcea Therapeutics

Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Segment by Type

RNA Interference

Antisense Oligonucleotides

Transthyretin Tetramer Stabilizer

Other

Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Segment by Application

Hospital and Clinic

Retail Pharmacies

Other

Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Manufacturers (2021-2026) Table 8. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue of Manufacturers (2021-2026) Table 9. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN), Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN), Product Type & Application Table 14. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Tonghua Zhongsheng Pharmaceutical Company Information Table 19. Tonghua Zhongsheng Pharmaceutical Business Overview Table 20. Tonghua Zhongsheng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Tonghua Zhongsheng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio Table 22. Tonghua Zhongsheng Pharmaceutical Recent Developments Table 23. Zhengzhou Taifeng Pharmaceutical Company Information Table 24. Zhengzhou Taifeng Pharmaceutical Business Overview Table 25. Zhengzhou Taifeng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Zhengzhou Taifeng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio Table 27. Zhengzhou Taifeng Pharmaceutical Recent Developments Table 28. Shapuaisi Pharma Company Information Table 29. Shapuaisi Pharma Business Overview Table 30. Shapuaisi Pharma Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Shapuaisi Pharma Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio Table 32. Shapuaisi Pharma Recent Developments Table 33. Luoxin Pharmaceutical Company Information Table 34. Luoxin Pharmaceutical Business Overview Table 35. Luoxin Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Luoxin Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio Table 37. Luoxin Pharmaceutical Recent Developments Table 38. Zydus Pharms Company Information Table 39. Zydus Pharms Business Overview Table 40. Zydus Pharms Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Zydus Pharms Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio Table 42. Zydus Pharms Recent Developments Table 43. Teva Company Information Table 44. Teva Business Overview Table 45. Teva Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Teva Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio Table 47. Teva Recent Developments Table 48. Pfizer Company Information Table 49. Pfizer Business Overview Table 50. Pfizer Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Pfizer Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio Table 52. Pfizer Recent Developments Table 53. Avet Pharmaceuticals Company Information Table 54. Avet Pharmaceuticals Business Overview Table 55. Avet Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Avet Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio Table 57. Avet Pharmaceuticals Recent Developments Table 58. AstraZeneca Company Information Table 59. AstraZeneca Business Overview Table 60. AstraZeneca Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. AstraZeneca Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio Table 62. AstraZeneca Recent Developments Table 63. Alnylam Pharmaceuticals Company Information Table 64. Alnylam Pharmaceuticals Business Overview Table 65. Alnylam Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Alnylam Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio Table 67. Alnylam Pharmaceuticals Recent Developments Table 68. Akcea Therapeutics Company Information Table 69. Akcea Therapeutics Business Overview Table 70. Akcea Therapeutics Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Akcea Therapeutics Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio Table 72. Akcea Therapeutics Recent Developments Table 73. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 74. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Region (2021-2026) & (K Units) Table 75. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Region (2021-2026) Table 76. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Region (2027-2032) & (K Units) Table 77. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Region (2027-2032) Table 78. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Region (2021-2026) & (US$ Million) Table 79. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Region (2021-2026) Table 80. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Region (2027-2032) & (US$ Million) Table 81. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Region (2027-2032) Table 82. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 83. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2021-2026) & (K Units) Table 84. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2027-2032) & (K Units) Table 85. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Country (2021-2026) & (US$ Million) Table 86. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Country (2027-2032) & (US$ Million) Table 87. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2021-2026) & (K Units) Table 89. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2027-2032) & (K Units) Table 90. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Country (2021-2026) & (US$ Million) Table 91. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Country (2027-2032) & (US$ Million) Table 92. Asia Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. Asia Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2021-2026) & (K Units) Table 94. Asia Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2027-2032) & (K Units) Table 95. Asia Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Country (2021-2026) & (US$ Million) Table 96. Asia Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Country (2027-2032) & (US$ Million) Table 97. South America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. South America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2021-2026) & (K Units) Table 99. South America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2027-2032) & (K Units) Table 100. South America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Country (2021-2026) & (US$ Million) Table 101. South America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Country (2027-2032) & (US$ Million) Table 102. Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2021-2026) & (K Units) Table 104. Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2027-2032) & (K Units) Table 105. Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Country (2021-2026) & (US$ Million) Table 106. Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Country (2027-2032) & (US$ Million) Table 107. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2021-2026) & (K Units) Table 108. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2027-2032) & (K Units) Table 109. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Type (2021-2026) Table 110. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Type (2027-2032) Table 111. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Type (2021-2026) & (US$ Million) Table 112. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Type (2027-2032) & (US$ Million) Table 113. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Type (2021-2026) Table 114. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Type (2027-2032) Table 115. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Price by Type (2021-2026) & (US$/Unit) Table 116. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Price by Type (2027-2032) & (US$/Unit) Table 117. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2021-2026) & (K Units) Table 118. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2027-2032) & (K Units) Table 119. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Application (2021-2026) Table 120. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Application (2027-2032) Table 121. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Application (2021-2026) & (US$ Million) Table 122. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Application (2027-2032) & (US$ Million) Table 123. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Application (2021-2026) Table 124. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Application (2027-2032) Table 125. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Price by Application (2021-2026) & (US$/Unit) Table 126. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Price by Application (2027-2032) & (US$/Unit) Table 127. Key Raw Materials Table 128. Raw Materials Key Suppliers Table 129. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Distributors List Table 130. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Customers List Table 131. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Trends Table 132. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Drivers Table 133. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Restraints Table 134. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Image Figure 5. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size (2021-2032) & (US$ Million) Figure 7. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (2021-2032) & (K Units) Figure 8. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Average Price (US$/Unit) & (2021-2032) Figure 9. RNA Interference Product Image Figure 10. Antisense Oligonucleotides Product Image Figure 11. Transthyretin Tetramer Stabilizer Product Image Figure 12. Other Product Image Figure 13. Hospital and Clinic Product Image Figure 14. Retail Pharmacies Product Image Figure 15. Other Product Image Figure 16. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Share by Manufacturers in 2025 Figure 17. Global Manufacturers of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN), Manufacturing Sites & Headquarters Figure 18. Global Top 5 and 10 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Players Market Share by Revenue in 2025 Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 21. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Region in 2025 Figure 22. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Region in 2025 Figure 23. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Country in 2025 Figure 24. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Country (2021-2032) Figure 25. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Country (2021-2032) Figure 26. United States Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Canada Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Mexico Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Country in 2025 Figure 30. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Country (2021-2032) Figure 31. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Country (2021-2032) Figure 32. Germany Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. France Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. U.K. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Italy Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Russia Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Spain Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Netherlands Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Switzerland Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Sweden Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Poland Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Asia Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Country in 2025 Figure 43. Asia Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Country (2021-2032) Figure 44. Asia Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Country (2021-2032) Figure 45. China Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Japan Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. South Korea Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. India Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Australia Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Taiwan Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. South America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Country in 2025 Figure 54. South America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Country (2021-2032) Figure 55. South America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Country (2021-2032) Figure 56. Brazil Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Argentina Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Chile Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Colombia Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Country in 2025 Figure 61. Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Country (2021-2032) Figure 62. Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Country (2021-2032) Figure 63. Egypt Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. South Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Israel Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Türkiye Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. GCC Countries Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Type (2021-2032) Figure 69. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Type (2021-2032) Figure 70. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Price (US$/Unit) by Type (2021-2032) Figure 71. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Application (2021-2032) Figure 72. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Application (2021-2032) Figure 73. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Price (US$/Unit) by Application (2021-2032) Figure 74. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Value Chain Figure 75. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Production Mode & Process Figure 76. Direct Comparison with Distribution Share Figure 77. Distributors Profiles Figure 78. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Opportunities and Challenges

Scope & coverage.

Types
  • RNA Interference
  • Antisense Oligonucleotides
  • Transthyretin Tetramer Stabilizer
  • Other
Applications
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Companies covered
  • Tonghua Zhongsheng Pharmaceutical
  • Zhengzhou Taifeng Pharmaceutical
  • Shapuaisi Pharma
  • Luoxin Pharmaceutical
  • Zydus Pharms
  • Teva
  • Pfizer
  • Avet Pharmaceuticals
  • AstraZeneca
  • Alnylam Pharmaceuticals
  • Akcea Therapeutics

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size (2021-2032)
  4. 2.2.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (2021-2032)
  5. 2.2.3 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Average Price (2021-2032)
  6. 2.3 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 RNA Interference
  9. 2.3.3 Antisense Oligonucleotides
  10. 2.3.4 Transthyretin Tetramer Stabilizer
  11. 2.3.5 Other
  12. 2.4 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) by Application
  13. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  14. 2.4.2 Hospital and Clinic
  15. 2.4.3 Retail Pharmacies
  16. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN), Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN), Product Type & Application
  8. 3.8 Global Manufacturers of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN), Established Date
  9. 3.9 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Tonghua Zhongsheng Pharmaceutical
  2. 4.1.1 Tonghua Zhongsheng Pharmaceutical Company Information
  3. 4.1.2 Tonghua Zhongsheng Pharmaceutical Business Overview
  4. 4.1.3 Tonghua Zhongsheng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Tonghua Zhongsheng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio
  6. 4.1.5 Tonghua Zhongsheng Pharmaceutical Recent Developments
  7. 4.2 Zhengzhou Taifeng Pharmaceutical
  8. 4.2.1 Zhengzhou Taifeng Pharmaceutical Company Information
  9. 4.2.2 Zhengzhou Taifeng Pharmaceutical Business Overview
  10. 4.2.3 Zhengzhou Taifeng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Zhengzhou Taifeng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio
  12. 4.2.5 Zhengzhou Taifeng Pharmaceutical Recent Developments
  13. 4.3 Shapuaisi Pharma
  14. 4.3.1 Shapuaisi Pharma Company Information
  15. 4.3.2 Shapuaisi Pharma Business Overview
  16. 4.3.3 Shapuaisi Pharma Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Shapuaisi Pharma Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio
  18. 4.3.5 Shapuaisi Pharma Recent Developments
  19. 4.4 Luoxin Pharmaceutical
  20. 4.4.1 Luoxin Pharmaceutical Company Information
  21. 4.4.2 Luoxin Pharmaceutical Business Overview
  22. 4.4.3 Luoxin Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Luoxin Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio
  24. 4.4.5 Luoxin Pharmaceutical Recent Developments
  25. 4.5 Zydus Pharms
  26. 4.5.1 Zydus Pharms Company Information
  27. 4.5.2 Zydus Pharms Business Overview
  28. 4.5.3 Zydus Pharms Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Zydus Pharms Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio
  30. 4.5.5 Zydus Pharms Recent Developments
  31. 4.6 Teva
  32. 4.6.1 Teva Company Information
  33. 4.6.2 Teva Business Overview
  34. 4.6.3 Teva Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Teva Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio
  36. 4.6.5 Teva Recent Developments
  37. 4.7 Pfizer
  38. 4.7.1 Pfizer Company Information
  39. 4.7.2 Pfizer Business Overview
  40. 4.7.3 Pfizer Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Pfizer Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio
  42. 4.7.5 Pfizer Recent Developments
  43. 4.8 Avet Pharmaceuticals
  44. 4.8.1 Avet Pharmaceuticals Company Information
  45. 4.8.2 Avet Pharmaceuticals Business Overview
  46. 4.8.3 Avet Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Avet Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio
  48. 4.8.5 Avet Pharmaceuticals Recent Developments
  49. 4.9 AstraZeneca
  50. 4.9.1 AstraZeneca Company Information
  51. 4.9.2 AstraZeneca Business Overview
  52. 4.9.3 AstraZeneca Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 AstraZeneca Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio
  54. 4.9.5 AstraZeneca Recent Developments
  55. 4.10 Alnylam Pharmaceuticals
  56. 4.10.1 Alnylam Pharmaceuticals Company Information
  57. 4.10.2 Alnylam Pharmaceuticals Business Overview
  58. 4.10.3 Alnylam Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Alnylam Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio
  60. 4.10.5 Alnylam Pharmaceuticals Recent Developments
  61. 4.11 Akcea Therapeutics
  62. 4.11.1 Akcea Therapeutics Company Information
  63. 4.11.2 Akcea Therapeutics Business Overview
  64. 4.11.3 Akcea Therapeutics Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Akcea Therapeutics Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio
  66. 4.11.5 Akcea Therapeutics Recent Developments
5 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Scenario by Region
  1. 5.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Region: 2021-2032
  3. 5.2.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Region: 2021-2026
  4. 5.2.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Region: 2027-2032
  5. 5.3 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Region: 2021-2032
  6. 5.3.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Region: 2021-2026
  7. 5.3.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Region: 2027-2032
  8. 5.4 North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Facts & Figures by Country
  9. 5.4.1 North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2021-2032)
  11. 5.4.3 North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Facts & Figures by Country
  16. 5.5.1 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2021-2032)
  18. 5.5.3 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Facts & Figures by Country
  41. 5.7.1 South America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2021-2032)
  43. 5.7.3 South America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.7.7 Colombia
  48. 5.8 Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Facts & Figures by Country
  49. 5.8.1 Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Country: 2021 VS 2025 VS 2032
  50. 5.8.2 Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2021-2032)
  51. 5.8.3 Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Country (2021-2032)
  52. 5.8.4 Egypt
  53. 5.8.5 South Africa
  54. 5.8.6 Israel
  55. 5.8.7 Türkiye
  56. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2021-2032)
  2. 6.1.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Type (2021-2032)
  4. 6.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Type (2021-2032)
  5. 6.2.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2021-2032)
  2. 7.1.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Application (2021-2032)
  4. 7.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Application (2021-2032)
  5. 7.2.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Value Chain Analysis
  2. 8.1.1 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Production Mode & Process
  5. 8.2 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Distributors
  8. 8.2.3 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Customers
9 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Analyzing Market Dynamics
  1. 9.1 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Trends
  2. 9.2 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Drivers
  3. 9.3 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Opportunities and Challenges
  4. 9.4 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst